Latest Period
n/a
Security Snapshot
Evoke Pharma, Inc. - Common Shares (EVOK) Institutional Ownership
CUSIP: 30049G203
13F Institutional Holders and Ownership History from Q2 2022 to Q3 2024
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Shares
- Symbol
- EVOK on Nasdaq
- Shares outstanding
- 1,582,162
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- EVOK - Evoke Pharma, Inc. - Common Shares is tracked under CUSIP 30049G203.
- Latest finished 13F holder period is not available.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 15 to 0 between Q2 2024 and Q3 2024.
- Reported value moved from $1,667,349 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Investment Quick Answers
What is CUSIP 30049G203?
CUSIP 30049G203 identifies EVOK - Evoke Pharma, Inc. - Common Shares in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 30049G203:
Significant Owners of Evoke Pharma, Inc. - Common Shares (EVOK) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 16% | $101,856 | 254,639 | Nantahala Capital Management, LLC | 03 Feb 2025 | |||
| Bleichroeder LP | 10% | 0% | $63,223 | 158,058 | -81% | Bleichroeder LP | 24 Mar 2025 |
Institutional Holders of Evoke Pharma, Inc. - Common Shares (EVOK) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2024 Q3 | 0 | $0 | -$1,666,575 | 0 | |
| 2024 Q2 | 3,151,890 | $1,667,349 | -$8,058 | $0.53 | 15 |
| 2024 Q1 | 3,163,387 | $1,929,665 | +$1,887,966 | $0.61 | 14 |
| 2023 Q4 | 68,360 | $71,786 | +$1,253 | $1.05 | 9 |
| 2023 Q3 | 67,157 | $92,405 | +$10,966 | $1.38 | 9 |
| 2023 Q2 | 59,166 | $97,415 | -$18,661 | $1.65 | 9 |
| 2023 Q1 | 68,914 | $131,127 | +$15,393 | $1.90 | 11 |
| 2022 Q4 | 60,640 | $161,234 | -$4,397 | $2.68 | 10 |
| 2022 Q3 | 62,420 | $117,009 | -$16,143 | $1.87 | 7 |
| 2022 Q2 | 70,180 | $228,016 | +$228,016 | $3.26 | 8 |